Loading
Etomoxir is an older drug, first tested for heart failure, that Numiera Therapeutics is developing to starve glioblastoma cells of the fats they burn for energy. It has an FDA orphan designation for malignant glioma.
Etomoxir was developed as a CPT1 inhibitor and tested in congestive heart failure, where a phase 2 trial was stopped after raised liver enzymes in 4 of 226 patients, according to the developer's history of the drug. Numiera Therapeutics is repurposing it for malignant glioma, including glioblastoma, on the basis that glioblastoma cells rely on fatty acid oxidation. The FDA granted orphan designation for the treatment of malignant glioma on 12 November 2024. The evidence in glioma is preclinical, from cell and mouse models; no cancer trial results have been published.
Inhibits carnitine palmitoyltransferase 1 (CPT1), the transporter that moves fatty acids into mitochondria, so cancer cells that depend on fatty acid oxidation lose an energy source.
1.Etomoxir slips into a pocket on its target.
treatment of malignant glioma
FDA orphan drug designation for etomoxir, sponsor Numiera Therapeutics source
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Etomoxir" OR ABSTRACT:"Etomoxir") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Etomoxir, not a curated reading list.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/